These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 1624558)

  • 1. Method for detection of simian immunodeficiency virus neutralizing antibodies using a noncommercial antigen capture enzyme-linked immunosorbent assay.
    Welch MJ; Thouless ME
    J Clin Microbiol; 1992 Jun; 30(6):1424-7. PubMed ID: 1624558
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of simian immunodeficiency virus isolation, titration, and neutralization assays which use whole blood from rhesus monkeys and an antigen capture enzyme-linked immunosorbent assay.
    Lohman BL; Higgins J; Marthas ML; Marx PA; Pedersen NC
    J Clin Microbiol; 1991 Oct; 29(10):2187-92. PubMed ID: 1939569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of simian immunodeficiency virus and human immunodeficiency virus type 2 capsid antigens by a monoclonal antibody-based antigen capture assay.
    Lairmore MD; Hofheinz DE; Letvin NL; Stoner CS; Pearlman S; Toedter GP
    AIDS Res Hum Retroviruses; 1993 Jun; 9(6):565-71. PubMed ID: 7688521
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel assay for antibody-dependent cell-mediated cytotoxicity against HIV-1- or SIV-infected cells reveals incomplete overlap with antibodies measured by neutralization and binding assays.
    Alpert MD; Heyer LN; Williams DE; Harvey JD; Greenough T; Allhorn M; Evans DT
    J Virol; 2012 Nov; 86(22):12039-52. PubMed ID: 22933282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Simian immunodeficiency virus (SIV)/immunoglobulin G immune complexes in SIV-infected macaques block detection of CD16 but not cytolytic activity of natural killer cells.
    Wei Q; Stallworth JW; Vance PJ; Hoxie JA; Fultz PN
    Clin Vaccine Immunol; 2006 Jul; 13(7):768-78. PubMed ID: 16829614
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidence for simian immunodeficiency virus-specific IgM and IgG response in peripheral blood mononuclear cells of serum enzyme-linked immunosorbent assay-negative nonhuman primates.
    Jehuda-Cohen T; Powell JD; Villinger F; Mayne AE; Sell KW; Ansari AA
    J Acquir Immune Defic Syndr (1988); 1994 Jun; 7(6):539-50. PubMed ID: 8176639
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Breadth and magnitude of antigen-specific antibody responses in the control of plasma viremia in simian immunodeficiency virus infected macaques.
    Pahar B; Kenway-Lynch CS; Marx P; Srivastav SK; LaBranche C; Montefiori DC; Das A
    Virol J; 2016 Dec; 13(1):200. PubMed ID: 27903274
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SIV, STLV-I and type D retrovirus antibodies in captive rhesus macaques and immunoblot reactivity to SIV p27 in human and rhesus monkey sera.
    Lairmore MD; Lerche NW; Schultz KT; Stone CM; Brown BG; Hermann LM; Yee JA; Jennings M
    AIDS Res Hum Retroviruses; 1990 Nov; 6(11):1233-8. PubMed ID: 1706606
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccine-induced neutralizing antibodies directed in part to the simian immunodeficiency virus (SIV) V2 domain were unable to protect rhesus monkeys from SIV experimental challenge.
    Schlienger K; Montefiori DC; Mancini M; Rivière Y; Tiollais P; Michel ML
    J Virol; 1994 Oct; 68(10):6578-88. PubMed ID: 7521918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early appearance of simian immunodeficiency virus (SIV) antigen and antibodies as variables in evaluating antiviral drugs in macaques.
    Ljungdahl-Ståhle E; Trojnar J; Oberg B; Wahren B
    J Virol Methods; 1992 Apr; 37(1):43-53. PubMed ID: 1533400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Isolation of potent neutralizing monoclonal antibodies from an SIV-Infected rhesus macaque by phage display.
    Kuwata T; Katsumata Y; Takaki K; Miura T; Igarashi T
    AIDS Res Hum Retroviruses; 2011 May; 27(5):487-500. PubMed ID: 20854170
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody-dependent enhancement and neutralization pattern of sera from SIV-infected or HIV-2-vaccinated rhesus monkeys.
    Le Grand R; Vogt G; Chapel A; Dormont D
    J Med Primatol; 1991 Jun; 20(4):172-6. PubMed ID: 1942007
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simian immunodeficiency virus (SIV) envelope-specific Fabs with high-level homologous neutralizing activity: recovery from a long-term-nonprogressor SIV-infected macaque.
    Glamann J; Burton DR; Parren PW; Ditzel HJ; Kent KA; Arnold C; Montefiori D; Hirsch VM
    J Virol; 1998 Jan; 72(1):585-92. PubMed ID: 9420262
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SIV- and HIV-2-neutralising antibodies in infected macaques measured by a novel and simple neutralisation test based on a non-commercial antigen-ELISA.
    Makoschey B; Faisst AC; Le Grand R; Coulibaly C; Stahl-Hennig C; Hunsmann G
    J Virol Methods; 1994 Dec; 50(1-3):257-68. PubMed ID: 7714049
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Passive immunization of rhesus macaques against SIV infection and disease.
    Gardner M; Rosenthal A; Jennings M; Yee J; Antipa L; Robinson E
    AIDS Res Hum Retroviruses; 1995 Jul; 11(7):843-54. PubMed ID: 7546912
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Specific N-linked and O-linked glycosylation modifications in the envelope V1 domain of simian immunodeficiency virus variants that evolve in the host alter recognition by neutralizing antibodies.
    Chackerian B; Rudensey LM; Overbaugh J
    J Virol; 1997 Oct; 71(10):7719-27. PubMed ID: 9311856
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of a CD4-expressing macaque cell line that can detect virus after a single replication cycle and can be infected by diverse simian immunodeficiency virus isolates.
    Chackerian B; Haigwood NL; Overbaugh J
    Virology; 1995 Nov; 213(2):386-94. PubMed ID: 7491763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determination of a statistically valid neutralization titer in plasma that confers protection against simian-human immunodeficiency virus challenge following passive transfer of high-titered neutralizing antibodies.
    Nishimura Y; Igarashi T; Haigwood N; Sadjadpour R; Plishka RJ; Buckler-White A; Shibata R; Martin MA
    J Virol; 2002 Mar; 76(5):2123-30. PubMed ID: 11836389
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors.
    Dhillon AK; Donners H; Pantophlet R; Johnson WE; Decker JM; Shaw GM; Lee FH; Richman DD; Doms RW; Vanham G; Burton DR
    J Virol; 2007 Jun; 81(12):6548-62. PubMed ID: 17409160
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mucosal challenge of Macaca nemestrina with simian immunodeficiency virus (SIV) following SIV nucleocapsid mutant DNA vaccination.
    Gorelick RJ; Lifson JD; Yovandich JL; Rossio JL; Piatak M; Scarzello AJ; Knott WB; Bess JW; Fisher BA; Flynn BM; Henderson LE; Arthur LO; Benveniste RE
    J Med Primatol; 2000 Aug; 29(3-4):209-19. PubMed ID: 11085583
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.